Optimizing the Management of Staphylococcus Aureus Bacteremia (OPTIMUS-SAB)
Launched by UNIVERSITY OF ALBERTA · Mar 23, 2024
Trial Information
Current as of June 20, 2025
Recruiting
Keywords
ClinConnect Summary
The OPTIMUS-SAB clinical trial is focused on improving the care of patients with Staphylococcus aureus bacteremia (SAB), a serious bloodstream infection that can lead to significant health risks, especially for vulnerable individuals. The study aims to implement a new care model in Alberta, Canada, where a specialized team will be notified when a patient's blood test shows Staphylococcus aureus. This team will then review the patient's medical information and make treatment recommendations based on proven best practices. By doing this, the researchers hope to enhance the quality of care, which could lead to shorter hospital stays, fewer readmissions, and better outcomes for patients.
To participate in this trial, individuals must be at least 18 years old, have a confirmed diagnosis of SAB from a blood test, and be admitted to one of the participating hospitals in Alberta. Unfortunately, patients who are critically ill or transferred from another hospital with a prior SAB diagnosis will not be eligible. Those who join the trial can expect to receive care that follows the latest guidelines, which may help improve their recovery from this infection. Overall, this study is about finding better ways to manage a serious condition and potentially save lives while also reducing healthcare costs.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age greater than 18 years at the time of hospital admission
- • Confirmed S. aureus bacteremia by blood culture performed at a laboratory in Alberta, Canada
- • Admitted to a designated acute care site in Alberta, Canada
- Exclusion Criteria:
- • The treating team believes death is imminent or inevitable .
- • GCD are C-level within 48 hours of admission.
- • The patient is transferred in from an out-of-province acute care center with a pre-existing SAB diagnosis.
About University Of Alberta
The University of Alberta, a leading research institution in Canada, is dedicated to advancing healthcare through innovative clinical trials. With a strong commitment to scientific excellence and community health, the university facilitates cutting-edge research across various medical disciplines. Its interdisciplinary approach fosters collaboration among researchers, clinicians, and students, ensuring that clinical trials are designed and conducted with the utmost rigor and ethical standards. By leveraging its extensive resources and expertise, the University of Alberta aims to translate research findings into meaningful advancements in patient care and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Edmonton, Alberta, Canada
Calgary, Alberta, Canada
Edmonton, Alberta, Canada
Edmonton, Alberta, Canada
Calgary, Alberta, Canada
Edmonton, Alberta, Canada
Calgary, Alberta, Canada
Edmonton, Alberta, Canada
Edmonton, Alberta, Canada
Calgary, Alberta, Canada
Camrose, Alberta, Canada
Fort Mcmurray, Alberta, Canada
Lethbridge, Alberta, Canada
Medicine Hat, Alberta, Canada
St. Albert, Alberta, Canada
Fort Saskatchewan, Alberta, Canada
Athabasca, Alberta, Canada
Banff, Alberta, Canada
Barrhead, Alberta, Canada
Bassano, Alberta, Canada
Beaverlodge, Alberta, Canada
Black Diamond, Alberta, Canada
Bonnyville, Alberta, Canada
Bow Island, Alberta, Canada
Boyle, Alberta, Canada
Brooks, Alberta, Canada
Calgary, Alberta, Canada
Canmore, Alberta, Canada
Cardston, Alberta, Canada
Castor, Alberta, Canada
Claresholm, Alberta, Canada
Coaldale, Alberta, Canada
Cold Lake, Alberta, Canada
Consort, Alberta, Canada
Coronation, Alberta, Canada
Crowsnest Pass, Alberta, Canada
Daysland, Alberta, Canada
Devon, Alberta, Canada
Didsbury, Alberta, Canada
Drayton Valley, Alberta, Canada
Drumheller, Alberta, Canada
Edson, Alberta, Canada
Elk Point, Alberta, Canada
Fairview, Alberta, Canada
Fort Vermilion, Alberta, Canada
Fox Creek, Alberta, Canada
Grande Cache, Alberta, Canada
Grande Prairie, Alberta, Canada
Grimshaw, Alberta, Canada
Hanna, Alberta, Canada
Hardisty, Alberta, Canada
High Level, Alberta, Canada
High Prairie, Alberta, Canada
High River, Alberta, Canada
Hinton, Alberta, Canada
Innisfail, Alberta, Canada
Jasper, Alberta, Canada
Killam, Alberta, Canada
Lac La Biche, Alberta, Canada
Lacombe, Alberta, Canada
Lamont, Alberta, Canada
Leduc, Alberta, Canada
Lloydminster, Alberta, Canada
Manning, Alberta, Canada
Mayerthorpe, Alberta, Canada
Mclennan, Alberta, Canada
Olds, Alberta, Canada
Oyen, Alberta, Canada
Peace River, Alberta, Canada
Pincher Creek, Alberta, Canada
Ponoka, Alberta, Canada
Provost, Alberta, Canada
Raymond, Alberta, Canada
Red Deer, Alberta, Canada
Redwater, Alberta, Canada
Rimbey, Alberta, Canada
Rocky Mountain House, Alberta, Canada
Rockyview, Alberta, Canada
Slave Lake, Alberta, Canada
Smoky Lake, Alberta, Canada
Spirit River, Alberta, Canada
St. Paul, Alberta, Canada
Stettler, Alberta, Canada
Strathmore, Alberta, Canada
Sundre, Alberta, Canada
Swan Hills, Alberta, Canada
Taber, Alberta, Canada
Three Hills, Alberta, Canada
Tofield, Alberta, Canada
Two Hills, Alberta, Canada
Valleyview, Alberta, Canada
Vegreville, Alberta, Canada
Vermilion, Alberta, Canada
Viking, Alberta, Canada
Vulcan, Alberta, Canada
Wabasca, Alberta, Canada
Wainwright, Alberta, Canada
Westlock, Alberta, Canada
Westview, Alberta, Canada
Wetaskiwin, Alberta, Canada
Whitecourt, Alberta, Canada
Patients applied
Trial Officials
Justin Chen, MD
Principal Investigator
University of Alberta
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported